Pharmacokinetics of Single-dose Dolutegravir in HIV-seronegative Subjects With Severe Hepatic Impairment Compared to Matched Controls.

NCT03813979 · clinicaltrials.gov ↗

PHASE4

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped difficult recruitment and delay due to COVID19

Conditions

HIV-1-infection
Hepatic Impairment

Interventions

DRUG: Dolutegravir

Sponsor

Radboud University Medical Center

Collaborators

[object Object]
[object Object]
[object Object]